Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Tanaka Miseri Chiome Bioscience Inc.
CONTACT
General Affairs and Human Resources Department Chiome Bioscience Inc.
CONTACT
Lead
Chiome Bioscience Inc.
To evaluate safety and efficacy of CBA-1205 in the following five parts in a stepwise manner: Part 1 * In Part 1, safety and tolerability in patients with Solid Tumor where no standard treatment is available, or who are intolerable or non-responder to the standard treatment will be evaluated. Initial dose for Part 2 will be determined. Part 2 * In Part 2, safety and tolerability in patients with advanced and/or recurrent Hepatocellular Carcinoma which are unresectable, or who are intolerable or non-responder to the standard treatment will be evaluated. Recommended dose in this population will be determined. Part 3 * In Part 3, safety and efficacy at the recommended dose in patients with advanced and/or recurrent Hepatocellular Carcinoma which are unresectable, or who are intolerable or non-responder to the standard treatment will be evaluated. Part 4 * In Part 4, safety and efficacy in patients with Malignant Melanoma who are refractory or intolerant to standard therapy. Part 5 * In Part 5, safety, tolerability and the recommended dose of the study drug in patients with Pediatric Cancer where no standard treatment is available, or who are intolerable or non-responder to the standard treatment will be evaluated. PK analysis
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted